Blood Lipid Profile In Patients Research Articles

Effects of biologic drug therapy on body weight, appetite, and blood lipid profile in patients with psoriasis

Obesity and dyslipidemia are frequently observed in patients with psoriasis. This study aimed to evaluate the effects of biological therapy on body weight (BW), body mass index (BMI), appetite, and blood lipid profiles in patients with psoriasis. A total of 83 patients receiving biologic therapy (n=44) [anti-tumor necrosis factor alpha (anti-TNFα) (n=5), interleukin (IL)-12/23 inhibitor (n=13), IL-17 inhibitor (n=20), and IL-23 inhibitor (n=6)] and conventional therapy (n=39) [methotrexate (MTX) (n=25) and acitretin (n=14)] were included in the study. The patient’s baseline and current BW, BMI, waist circumference, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), plasma triglyceride values, and Psoriasis Area and Severity Index (PASI) were retrospectively screened. Appetite was assessed with the Simplified Nutritional Appetite Questionnaire (SNAQ). The mean BW percent change values were found to increase by 2.40±2.30 kg, 2.38±4.13 kg, and 0.40±3.47 kg in patients taking anti-TNFα, IL-12/23 inhibitor, and IL-17 inhibitor agents, respectively, decrease by -0.60±0.89 kg in those receiving an IL-23 inhibitor; increase by 0.52±3.40 kg and 1.38±2.79 kg in those receiving MTX and acitretin, respectively. The triglyceride percent change rates increased with MTX (27.46±52.87 mg/dl) (p=0.029). Anti-TNFα and ixekizumab increased HDL percent change rates (21.44±20.99 mg/dl and 24.4±35.40 mg/dl, respectively) (p=0.044 and p=0.005). Although the SNAQ scores were similar in patients using conventional and biological drugs, a negative correlation was observed between the SNAQ scores and the PASI change (p=0.049, r=-0.221). In addition, an increase in BMI had a negative correlation with the PASI change (p=0.01, r=-0.282). Anti-TNFα and IL-12-23 inhibitors increased BW. While MTX increased triglyceride levels, anti-TNFα and ixekizumab increased HDL levels. In the treatment of psoriasis, the presence of obesity and blood lipid profiles should be considered in the selection of the appropriate treatment for each patient.

Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.

Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes. At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC ≥ 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC < 200 mg/dl. Conversely, patients with TG ≥150 mg/dl displayed shorter PFS (3.4 vs. 5.1 months, P = .02) and OS (7.1 vs. 12.9 months, P = .009) compared to those with TG <150 mg/dl. TC and TG were then combined in a "LIPID score" identifying three subgroups: good-risk (GR) (TC ≥200 mg/dl and TG <150 mg/dl), intermediate-risk (IR) (TC <200 mg/dl and TG <150 mg/dl or TC ≥200 mg/dl and TG ≥150 mg/dl) and poor-risk (PR) (TC <200 mg/dl and TG ≥150 mg/dl). The mPFS of GR, IR, and PR groups was 7.8, 4.3, and 2.5 months, respectively (P = .005); mOS of GR, IR, and PR was 20.4, 12.4, and 5.3 months, respectively (P < .001). At multivariable analysis, the PR profile represented an independent poor prognostic factor for both PFS and OS. We developed a lipid score that defined subgroups of patients with cancer who differently benefit from ICIs. Further mechanistic insights are warranted to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs.

Effect of Statins on the Blood Lipid Profile in Patients with Different Cardiovascular Diseases: A Systematic Review with Meta-analysis of Randomized Clinical Trials.

Statins are the main lipid-lowering drugs and are used in the prevention of cardiovascular diseases (CVDs). Since the results have been, to some extent, inconsistent in the clinical trials concerning different types of CVDs, a systematic review and meta-analysis was performed to prove the effect of statins on decreasing elevated levels of total cholesterol, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in patients with CVDs. Literature search was performed on major electronic databases (MEDLINE/ PubMed, Scopus, and ISI Web of Science) from inception up to July 2021 to find randomized controlled trials (RCTs) evaluating the effect of different statins on different types of CVDs. The effect size was determined using weighted mean difference (WMD) and corresponding 95% confidence interval (CI). Statin therapy significantly decreased levels of total cholesterol (WMD = -33.37 mg/dl, 95% CI: -45.98 to -20.76, P<0.001), LDL-C (WMD = -29.42 mg/dl, 95% CI: -36.81 to -22.03, P<0.001), and TG (WMD = -15.19 mg/dl, 95% CI = -26.41 to -3.97, P<0.001), and increased levels of HDL-C (WMD = 1.55 mg/dl, 95% CI: 0.20, to 2.90, P=0.02) in patients with different CVDs. Statin therapy was found effective in lowering levels of total cholesterol, LDL-C, and TG, and increasing levels of HDL-C in patients with different CVDs.

Impact of diabetes and hypertension for the development of cardiovascular diseases: a systematic review

This study aimed to systematically evaluate the evidence respecting the association of risk factors for the development of cardiovascular disease (CVD) among patients with diabetes and hypertension (HTN). Articles were searched from 2015 to 2022 through PubMed, MEDLINE, and Embase. The inclusion criteria included risk factors such as hemoglobin A1c (HbA1c), blood pressure measurement, body mass index, determining the glomerular filtration rate(GER), and blood lipid profile in patients with HTN and diabetes. The quality of the study was assessed by assessment Newcastle-Ottawa scale (NOS). After thorough research, only seven out of 170 articles were selected. The systolic blood pressure (SBP) and GER were calculated. All studies&amp;apos; quality was good under the NOS criteria. Generally, high HbA1c: 138 mmHg, high or low GFR: &amp;gt;60 ml/minute/1.75 m2), and increasing SBP (SBP from 120 to 139 to &amp;ge;140 mmHg) are great risk factors for CVD among diabetes and HTN patients. No data on blood lipid profile and body mass index was available among the selected studies. It was concluded that relatively well-controlled HTN and diabetes might reduce the risk factors for the development of CVD.

Effect of nucleos(t)ide analogues on blood lipid profiles in patients with chronic hepatitis B: A cross-sectional survey.

This study aimed to explore the effects of the 3 nucleos(t)ide analogues (NAs) on lipid levels. We retrospectively included patients treated with NAs at 2 centers and collected their clinical data at their visiting points. Differences in blood lipid levels were analyzed by statistical methods, and factors related to hyperlipidemia were discussed. In these 2 centers, the prevalence rates of hypercholesterolemia were 12/181 (6.6%) for tenofovir alafenamide fumarate (TAF)-, 0/158 (0%) for tenofovir disoproxil fumarate (TDF)-, and 13/182 (7.1%) for entecavir (ETV)-treated individuals (P = .003). The prevalence rates of hypertriglyceridemia were 30/181 (16.6%) for TAF-, 11/158 (7.0%) for TDF-, and 26/182 (14.3%) for ETV-treated individuals (P = .025). In TAF (n = 181, 10 [6, 15] months), TDF (n = 158, 18 [7.5, 45] months), and ETV (n = 182, 24 [10, 60] months) groups, total cholesterol (TC) levels were 4.63 ± 0.91 mmol/L, 3.86 ± 0.61 mmol/L, and 4.53 ± 0.87 mmol/L, respectively; triglyceride (TG) levels were 1.27 ± 0.76 mmol/L, 0.87 ± 0.51 mmol/L, and 1.14 ± 0.67 mmol/L, respectively (P < .001). In multivariate regression analysis, factors associated with hypercholesterolemia were age (adjusted hazard risk [HR] = 1.055 [1.018-1.094]; P = .003) and body mass index (BMI) (adjusted HR = 0.817 [0.669-0.998]; P = .048). Factors associated with hypertriglyceridemia were TAF group (vs. TDF group) (adjusted HR = 0.405 [0.167-0.980]; P = .045), age (adjusted HR = 1.028 [1.002-1.055]; P = .038), and sex (adjusted HR = 0.190 [0.079-0.456]; P < .001). Among the patients treated with TAF (10 [6, 15] months), TDF (18 [7.5, 45] months), and ETV (24 [10, 60] months), the blood lipid levels in the TDF group were lower than those in the TAF group and ETV group, and the occurrence of hyperlipidemia was associated with age, sex, BMI, and different treatment.

Lipid profile changes in patients with COVID-19 referred to medical centers in Kermanshah, Iran; a case-control study.

ObjectiveTo evaluate blood lipid profiles in patients with coronavirus disease 2019 (COVID-19), and to explore the association with disease severity.MethodsThis case–control study included patients with COVID-19, referred to two medical centers in Kermanshah, Iran (between July 2020 and December 2020), and healthy controls. Lipid profiles were evaluated in patients who were grouped according to severe (intensive care unit [ICU]), or less severe (outpatient), forms of COVID-19, and in healthy controls, and were compared among the three groups.ResultsA total of 132 participants were included, comprising ICU (n = 49), outpatient (n = 48) and control (n = 35) groups. Mean cholesterol levels were lower in the patient groups than in controls; high-density lipoprotein cholesterol (HDL-C) levels were higher in the ICU group versus outpatients, and low-density lipoprotein cholesterol (LDL-C) levels were lower in the ICU group versus outpatients. The frequency of diabetes and hypertension was higher in the ICU group than in the outpatient group. Furthermore, LDL-C level was associated with disease severity (odds ratio 0.966, 95% confidence interval 0.944, 0.989).ConclusionLipid profiles differ between severe and less severe forms of COVID-19. LDL-C level may be a useful indicator of COVID-19 severity.

Low serum level of apolipoprotein A1 may predict the severity of COVID-19: A retrospective study.

BackgroundDyslipidemia has been observed in patients with coronavirus disease 2019 (COVID‐19). This study aimed to investigate blood lipid profiles in patients with COVID‐19 and to explore their predictive values for COVID‐19 severity.MethodsA total of 142 consecutive patients with COVID‐19 were included in this single‐center retrospective study. Blood lipid profile characteristics were investigated in patients with COVID‐19 in comparison with 77 age‐ and gender‐matched healthy subjects, their predictive values for COVID‐19 severity were analyzed by using multivariable logistic regression analysis, and their prediction efficiencies were evaluated by using receiver operator characteristic (ROC) curves.ResultsThere were 125 and 17 cases in the non‐severe and severe groups, respectively. Total cholesterol (TC), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein cholesterol (LDL‐C), and apolipoprotein A1 (ApoA1) gradually decreased across the groups in the following order: healthy controls, non‐severe group, and severe group. ApoA1 was identified as an independent risk factor for COVID‐19 severity (adjusted odds ratio [OR]: 0.865, 95% confidence interval [CI]: 0.800–0.935, p < 0.001), along with interleukin‐6 (IL‐6) (adjusted OR: 1.097, 95% CI: 1.034–1.165, p = 0.002). ApoA1 exhibited the highest area under the ROC curve (AUC) among all single markers (AUC: 0.896, 95% CI: 0.834–0.941); moreover, the risk model established using ApoA1 and IL‐6 enhanced prediction efficiency (AUC: 0.977, 95% CI: 0.932–0.995).ConclusionBlood lipid profiles in patients with COVID‐19 are quite abnormal compared with those in healthy subjects, especially in severe cases. Serum ApoA1 may represent a good indicator for predicting the severity of COVID‐19.

Untargeted lipidomics reveals specific lipid abnormalities in systemic lupus erythematosus

To identify potential lipid biomarkers by studying changes in the blood lipid profile of patients with systemic lupus erythematosus (SLE) using lipidomics. Serum samples were collected from 115 SLE patients and 115 age- and sex-matched healthy controls (HCs). Lipid profiles were assessed using ultrahigh-performance liquid chromatography coupled with Q Exactive spectrometry, and possible lipid biomarkers were screened and evaluated by univariate and multivariate analyses. Metabolic phenotypes related to SLE disease activity index (SLEDAI) scores were detected in the serum of SLE patients, and these phenotypes indicated the activity of the disease. Alterations in energy metabolism, fatty acid metabolism and other pathways were observed in patients with SLE. Phosphatidylethanolamine (16:0/18:2), lysophosphatidylethanolamine (18:0), and acylcarnitine (11:0) can be used as biomarkers for the clinical diagnosis of SLE, and receiver operating characteristic (ROC) analysis indicated their effectiveness in diagnosing this disease. Our study identified serum biomarkers related to disease activity in patients with SLE, providing a basis for its clinical diagnosis.

Proatherogenic Changes in the Blood Lipid Profile in Patients with Cerebrovascular Disease and Type 2 Diabetes

The link between type 2 diabetes mellitus and atherosclerotic lesions in the cerebral arteries is one of the leading risk factors for acute and chronic cerebrovascular disease (CVD). Materials and methods: 126 patients with cerebrovascular disease (CVD) were examined to assess the proatherogenic blood changes: Group 1 consisted of 75 patients with CVD and type 2 diabetes mellitus (T2DM), aged 65 [55; 71] years, including 36 men; Group 2 consisted of 51 patients without T2DM, aged 66 [59; 72] years, including 23 men. The control group consisted of 32 people without CVD and T2DM, aged 63 [50; 67] years, including 17 men. All patients underwent a clinical examination, a range of biochemical blood tests, neuroimaging and vascular imaging studies. The results of the lipid panel (in particular, small dense LDL (sdLDL) and carbohydrate metabolism (glycated haemoglobin (HbA1c)) were the primary focus when the laboratory blood results were examined. Results: patients in the comorbidities group (CVD + T2DM) were more likely to have a history of CVD (52% versus 33.3% of all cases, p = 0.035) and haemodynamically significant carotid artery stenosis (38.6% versus 21.6%, p = 0.044). The concentration of hyperatherogenic sdLDL particles was also significantly higher in this group—49.1 [46.3; 53.7] mg/dL versus 33.4 [26.7; 45.6] mg/dL in patients with CVD but without T2DM, and 25.0 [19.9; 29.4] in the control group. At the same time, sdLDL values in Group 1 patients correlated with LDL, triglycerides, fasting glycaemia and HbA1c levels. Conclusion. Atherosclerotic plaques in the brachiocephalic arteries in CVD are accompanied by proatherogenic changes of the blood lipid spectrum. The sdLDL level is highest and correlates with the severity of carbohydrate metabolism disorders in patients with chronic CVD and T2DM.

Analisis asupan karbohidrat dan lemak serta aktivitas fisik terhadap profil lipid darah pada penderita penyakit jantung koroner

World Health Organization has estimated that the main cause of death in degenerative diseases is coronary heart disease (CHD). Coronary heart disease can be caused by narrowing of the blood vessels due to high levels of fat in the blood. This is due to excessive intake of fat and carbohydrates, and not doing physical activity or the body is not moving. This study aims to determine the blood lipid profile of outpatients with coronary heart disease. This descriptive-analytic study was used as a case-control study design, with a sample of 64 outpatients. The study was conducted at the Meuraxa Hospital Banda Aceh in March 2019. Intake data were collected using the SQ-FFQ method and physical activity data using the PAL method, while HDL, LDL, and triglyceride data were obtained through secondary data from hospital medical records. The statistical test was used by the Chi-Square test. The results showed that there was an effect of fat intake on blood lipid profiles in coronary heart disease patients (p= 0,006 with OR= 4,80), and the effect of carbohydrate intake (p= 0,032 and OR= 2,96), on the contrary, physical activity (p= 0,130) with a lipid profile showed no association. In conclusion, the intake of fat and carbohydrates has an effect on blood lipid profiles, but physical activity does not affect the blood lipid profiles of patients with coronary heart disease. Suggestions, it is necessary to maintain a balance of consumption of foods that are high in fat, and it is necessary to do consultations regarding low-fat diets

Association of Lipid Profile and Suicide Attempts in a Large Sample of First Episode Drug-Naive Patients With Major Depressive Disorder.

Several studies have reported a link between lipid disorders and suicidality. However, few studies have investigated the relationship between suicidal behavior and blood lipid profiles in patients with first-episode and drug-naive (FEDN) major depressive disorder (MDD). The main purpose of this study was to examine the relationship between plasma lipid profiles and suicide attempts in a large sample of FEDN MDD patients in the Chinese Han population, which has not been reported. A total of 1,718 MDD outpatients were recruited. Their clinical and demographic data as well as plasma lipid parameters were collected. We obtained suicide attempt data through interviews with patients and their family members. We rated the Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) for all patients. The suicide attempt rate of MDD patients was 20.14%, of which 13.68% in the last month and 6.46% in the past. Further, compared with non-attempters, suicide attempters had significantly higher total levels of cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c), higher HAMA and HAMD scores, but significantly lower high-density lipoprotein cholesterol (HDL-c) levels. Logistic regression analysis showed that suicide attempts were correlated with higher TC, lower HDL-c, and higher HAMA and HAMD scores with the adjusted odds ratio (OR) of 1.35, 0.52,1.28, and 1.08, respectively (all p < 0.05). Our findings suggest that FEDN patients with MDD have a high rate of attempted suicide. In the early stage of MDD patients, certain blood lipid parameters and more severe symptoms of anxiety and depression are correlated with suicide attempts. However, due to the cross-sectional design of this study, it is impossible to draw a causal relationship between lipid profiles and suicide attempts. Moreover, an inverse correlation can also be considered, that is, high cholesterol may be the consequence of suicide attempts and depression.

Effects of plant protein and animal protein on lipid profile, body weight and body mass index on patients with hypercholesterolemia: a systematic review and meta-analysis

We conducted a meta-analysis on the effect of plant protein or animal protein on body weight (BW), body mass index (BMI) and blood lipid profiles in patients with hypercholesterolemia. We used subject and free words to search PubMed, Embase and Cochrane Library databases. The risk-of-bias evaluation tool was used to assess literature quality. Data merging and statistical analyses were carried out using Review Manager 5.3 and Stata 13.0. All indicators were expressed as the mean difference (MD) and 95% confidence interval (95% CI). The heterogeneity test was conducted according to I2 and Q tests. We used Egger's test to evaluate publication bias quantitatively. This was a meta-analysis of intervention trials. Thirty-two studies (1562 patients) were included. The quality of the included studies was acceptable. Compared with consumption of animal protein, plant protein reduced total cholesterol (TC) (MD = - 0.19mmol/L, 95% CI - 0.26, - 0.12), triglyceride (MD = - 0.07mmol/L, 95% CI - 0.13, - 0.02), low-density lipoprotein cholesterol (LDL-C) (MD = - 0.19mmol/L, 95% CI - 0.26, - 0.13), very low-density lipoprotein cholesterol (MD = - 0.05mmol/L, 95% CI - 0.09, - 0.01), TC/LDL-C ratio (MD = - 0.17, 95% CI - 0.32, - 0.02) and LDL-C/HDL-C ratio (MD = - 0.20, 95% CI - 0.33, - 0.06) significantly and increased high-density lipoprotein cholesterol (HDL-C) (MD = 0.03mmol/L, 95% CI 0.01, 0.06) levels, but had no effect on BW (MD = - 0.41kg, 95% CI - 2.14, 1.33) or BMI (MD = 0.11kg/m2, 95% CI - 0.51, 0.73). Compared with animal protein, consumption of plant protein could improve lipid profile in patients with hypercholesterolemia.

The Comparison of Blood Lipid Profile in Patients with and Without Androgenetic Alopecia

The Comparison of Blood Lipid Profile in Patients with and Without Androgenetic Alopecia

Effect of proprotein convertase subtilisin/kexin type 9 inhibitor on blood lipid profile in patients with extremely high risk atherosclerotic cardiovascular disease

To investigate the lowering effect on lipid and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in patients with extremely high risk atherosclerotic cardiovascular disease (ASCVD). The outpatients and in-patients with extremely high risk ASCVD admitted to the Second Affiliated Hospital of Chongqing Medical University from April to October in 2019 were enrolled. The enrolled patients were divided into two groups by random number table method. The patients in the atorvastatin group were given only 20 mg atorvastatin orally every night for 4 weeks. In the combined group, oral atorvastatin was administered with subcutaneous injection of 140 mg evolocumab, a PCSK9 inhibitor, once every 2 weeks, and the course of treatment was 4 weeks. Serum lipid profile was measured before and 4 weeks after treatment, including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and lipoprotein-a (Lp-a). Adverse events were recorded. During the study period, a total of 40 patients were enrolled, with 20 patients in the atorvastatin group and 20 in the combined group. There was no significant difference in blood lipid profile before treatment between the two groups. After 4 weeks of treatment, the levels of TC and LDL-C in the two groups and Lp-a level in the combined group were significantly lower than those before treatment, while the levels of TG and HDL-C in the two groups were not statistically significant. Further analysis showed that the differences in TC, LDL-C and Lp-a between before and after treatment in the combined group were significantly higher than those in the atorvastatin group [TC difference (mmol/L): 2.78±1.98 vs. 0.54±0.83, LDL-C difference (mmol/L): 1.91±1.38 vs. 0.39±0.72, Lp-a difference (mg/L): 115.87±138.93 vs. -84.19±251.85, all P < 0.05]. Only 1 patient in the combined group developed allergic reaction, mainly manifested as skin rash, who alleviated after anti-allergic treatment. No other adverse reactions such as abnormal liver function and increased myozyme occurred in the two groups. PCSK9 inhibitor could rapidly and effectively reduced the levels of TC, LDL-C and Lp-a in extremely high risk ASCVD patients, while had little effect on the levels of TG and HDL-C. It is safe to some extent.

The influence of diabetes mellitus on blood lipid profile in patients with coronary vessel restenosis associated with Helicobacter pylori

Aim. To determine the influence of diabetes mellitus on the level of blood lipid profile in patients with coronary restenosis associated with H. pylori.&#x0D; Methods. The study included 50 patients with coronary artery disease and coronary restenosis associated with H. pylori infection. Patients were divided into 2 groups: with concomitant diabetes mellitus (group 1, n=10 patients) and without it (group 2, n=40). The groups were comparable by age, sex, and clinical and angiographic data. All patients along with basic therapy additionally received standard first-line anti-helicobacter therapy in accordance with the Maastricht Consensus-3 (2005) for 14 days. Before treatment and 90 days after treatment, blood lipid profile was evaluated with Siemens Dimension X pand plus device. To analyze the obtained digital data, the arithmetic mean of the indicator (M) and the error of the mean (m) were calculated. The statistical significance of the difference between the groups was determined by Pearson 2 test. Differences were considered significant at p 0.05. Statistical data processing was performed using the SPSS statistical package and the Excel-2013.&#x0D; Results. A comparative analysis of qualitative indicators showed that in both groups in most cases (90 and 87.5%, respectively), the level of low density lipids was above the norm, but they did not differ between the groups (2=0.047; р=0.828). After eradication in both groups, both qualitative (60 and 67.5% respectively) and quantitative values of low density lipids improved significantly (decreased to 98.28.6 and 97.67.9 mg/dl, respectively) however, no significant differences between the groups were found (p ˃0.05).&#x0D; Conclusion. A history of diabetes mellitus in patients with coronary restenosis associated with H. pylori cannot be considered as an additional factor that increases the likelihood of developing the disorders of lipid profile; successful eradication therapy in this category of patients contributes to the normalization of lipid profile regardless of the presence or absence of concomitant diabetes mellitus.

Changes in gut microbiota and blood lipid profile in patients with irritable bowel syndrome in association with obesity

Relevance of research. Irritable bowel syndrome (IBS) is considered the most common disease, the frequency of which reaches 20% of the population. It is often combined with obesity. An important role in the development of bothpathologies is the disturbance of the colonic microbiota.The purpose of the study is to investigate the nature of changes in the colon microflora in patients with IBS with constipation (IBSc) and their development on the background of obesity and to compare the results with the parameters of the lipid blood spectrum.Material and methods. We examined 32 patients with IBS on the background of obesity, 28 – with IBS without any other pathology and 18 healthy persons. All individuals were examined for the species and quantitative composition of the microflora by bacteriological methods, and the lipid profile of the blood by means of enzyme-colorimetric methods on the analytical modular test system Sovas 6000 from Roche Diagnostics firm (Switzerland).Results. It was established that both at IBSc and IBSc on the background of obesity there is a decrease in the level of bifidobacteria in the colonic microbiota by 13.0 and 14.1%, and lactobacillus - by 11.8 and 49.7%, respectively. In patients with this combined pathology, 1.89 and 1.95 times increased the number of clostridia that belong to the class of Firmicutes compared with healthy ones. At the same time, they have an elevated in 1,2 and 4,3 times level of St. Aureus and in 1,5 and 1,9 times E. coli. Increasing the number of Enterobacter cloacea and aeurogenes has also been established in IBSc and in combination with obesity. There are established direct correlational relationships between elevated levels in the intestinal microorganism of clostridium and St. aureus, and low density lipoprotein cholesterol concentration and triglyceride levels. Conclusion. In patients with IBSc and its combination with obesity, there is a decrease in the level of bifido- and lactobacilli, an increase in the number of Clostridia, Staphylococcus aureus, E. coli, Candida and Enterobacteria. Correlation relationships between microbial spectrum with Clostridium, Staphylococcus aureus and cholesterol of low density lipoprotein and triglycerides have been established, indicating the possible role of microorganisms in regulation of the lipid blood spectrum.

Investigating the impact of eight weeks of aerobic and resistance training on blood lipid profile in elderly with non-alcoholic fatty liver disease: a randomized clinical trial.

The aim of this study was to investigate the effects of eight weeks aerobic and resistance exercise on blood lipid profile in elderly with non-alcoholic fatty liver disease (NAFLD). Increased sedentary have a potential role in the development of NAFLD. Exercise training as an effective strategy to reduce NAFLD is presented. In a randomized clinical trial study, thirty nine elderly patients with NAFLD were enrolled and were randomly divided in three groups. Aerobic groups (AG, n=13), resistance group (RG, n=13) and control group (CG, n=13). AG participated in an 8-week aerobic training (three 45-min sessions per week at 55-75% of HRR (heart rate reserve)). RG participated in an 8-week resistance exercises (three 45-min sessions per week at 50-70% of 1RM (one-repetition measure). Blood lipid profile of patients were evaluated baseline and after eight weeks. At baseline, there were no differences between the two groups. In two group, cholesterol and low density lipoprotein (LDL) of blood of elderly follow eight weeks aerobic training with p=0.02 and p=0.02 were decreased, respectively. Also, High density lipoprotein (HDL) was improved follow aerobic training (p=0.008). However, the aerobic and resistance training were not effective on triglyceride (TG). aerobic training was more effective than resistance training in improving the blood lipid profile in elderly with NAFLD and can role in management of this condition.

Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis.

BackgroundMetformin is the first-choice drug for patients with Type 2 diabetes, and this therapy is characterized by being weight neutral. However, in the elderly an additional unintentional weight loss could be considered as an adverse effect of the treatment.ObjectivesWe aimed to perform a meta-analysis of placebo-controlled studies investigating the body weight changes upon metformin treatment in participants older than 60 years.Materials and methodsPubMed, EMBASE and the Cochrane Library were searched. We included at least 12 week-long studies with placebo control where the mean age of the metformin-treated patients was 60 years or older and the body weight changes of the patients were reported. We registered our protocol on PROSPERO (CRD42017055287).ResultsFrom the 971 articles identified by the search, 6 randomized placebo-controlled studies (RCTs) were included in the meta-analysis (n = 1541 participants). A raw difference of -2.23 kg (95% CI: -2.84 –-1.62 kg) body weight change was detected in the metformin-treated groups as compared with that of the placebo groups (p<0.001). Both total cholesterol (-0.184 mmol/L, p<0.001) and LDL cholesterol levels (-0.182 mmol/L, p<0.001) decreased upon metformin-treatment.ConclusionsOur meta-analysis of RCTs showed a small reduction of body weight together with slight improvement of the blood lipid profile in patients over 60 years. With regard to the risk of unintentional weight loss, metformin seems to be a safe agent in the population of over 60 years. Our results also suggest that metformin treatment may reduce the risk of major coronary events (-4-5%) and all-cause mortality (-2%) in elderly diabetic populations.

Clinical and epidemiological features of chronic pancreatitis course associated with atherosclerosis.

The article describes and analyzes dyslipidemic disorders, the degree of pancreatic external secretion insufficiency in patients with chronic pancreatitis. The purpose of our study is to study the changes in the blood lipid profile in patients with chronic pancreatitis depending on the degree of pancreatic external secretion insufficiency in residents of the city and villages. We carried out the 13C-mixed triglyceride respiratory test (13C-MTRT) and the 13C-amylase respiratory test (13C-ART) to detect the pancreatic external secretion insufficiency (PESI). Changes in the blood lipid profile were based on the violations in the lipidogram (determination of total blood cholesterol level (TC), triglycerides (TG), high density lipoproteins (HDL), and low density lipoproteins (LDL), atherogenicity coefficient (CA)). All examined patients with combination of chronic pancreatitis (CP) and athe­rosclerosis have lipid metabolism disorders, but the changes in the city residents are more significant as compared with the rural population. It was also found that the most pronounced violation of the PESI was observed in patients with CP and lipid metabolism disorders, who were residents of the city. In these patients, during the 13C- MTRT, the maximum concentration of 13СО2 between 150 and 210 minutes were at the level of 4.9±0.7%; total concentration of 13СО2 at the end of the study (360 min.) – 17,1±0,3% and were statistically significant in comparison with the control group.

DYSLIPIDEMIA AS A FACTOR FOR PROGRESSION OF RENAL OSTEODYSTROPHY AND CORONARY HEART DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON PERITONEAL DIALYSIS

Numerous studies of the last years focused on various links of pathogenesis and factors for progression of coronary heart disease (CHD) and chronic kidney disease (CKD) allowed to find intersection, such as progression of atherosclerosis or phosphorus and calcium and lipid imbalance, which lead to vascular calcareous infiltration, development of renal osteodystrophy and rising of cardiac risks.&#x0D; Purpose of the research: To define indicators of lipid exchange in patients on peritoneal dialysis which can be factors for progression of renal osteodystrophy and ischemic heart disease.&#x0D; Materials and methods. Indicators of lipid exchange, various types of renal osteodystrophy and clinical types of ischemic heart disease in 114 patients receiving peritoneal dialysis therapy in the Regional Clinical Center of Urology and Nephrology of V.I.Shapoval were analysed.&#x0D; Results. Having analysed changes in blood lipid profile of patients on peritoneal dialysis (PD), we found out a reliable growth of high-density lipoproteins (HDL) in a group of patients without signs of ischemic heart disease and in a group of patients having stable angina, whose primary types of renal osteodystrophy were osteoporosis and fibrous ostitis. Reliable differences had also very-low-density lipoproteins (VLDL) which also were the highest in a group of patients having stable angina without signs of cardiac decompensation. The average duration of PD treatment of patients of this group was 12,3 months.&#x0D; Conclusion. The results of the research confirmed that calcareous infiltration of vessels and heart valves on early stages of PD therapy is mainly caused by dyslipidemia and atherosclerotic changes and less by phosphorus and calcium imbalance which importance increases with duration of PD treatment.